Abiopharma

Serina Therapeutics Congratulates Juvenescence Ltd. on $150M Series B Funding and Strategic Partnership with M42

General Announcement: CHANGES IN SUBSTANTIAL SHAREHOLDERS INTEREST PURSUANT TO SECTION 138 OF THE COMPANIES ACT, 2016

FDA approve CLINDAMYCIN PHOSPHATE

FDA approve AZATHIOPRINE

FDA approve DIAZEPAM

FDA approve SILDENAFIL CITRATE

FDA approve LEVOCETIRIZINE DIHYDROCHLORIDE

FDA approve SAFINAMIDE MESYLATE

FDA approve EPLERENONE

FDA approve LEVOCETIRIZINE DIHYDROCHLORIDE

FDA approve HYDROXYCHLOROQUINE SULFATE

FDA approve NAPROXEN

FDA approve RIVASTIGMINE

FDA approve EPTIFIBATIDE

NYSE MKT symbol attribute type Test_mode was changed. Previous value: -. New value: N.